Targeted Genetics Corporation develops and commercializes molecular therapeutics that target the underlying cause of a variety of serious diseases that have significant unmet medical need. Our lead product candidate is being developed as a treatment for inflammatory arthritis, and additional programs target HIV/AIDS, congestive heart failure and Huntington's disease. Our diverse pipeline has been built on a solid foundation of intellectual property related to gene delivery, and on our core capabilities in critical functions that include preclinical development, clinical and regulatory affairs, and manufacturing of innovative gene-based product candidates. These assets and capabilities provide a broad spectrum of potential future market opportunities, as well as partnering or out-licensing opportunities.
Targeted Genetics is based in Seattle, Washington, and has approximately 65 employees. The Company has been public since May 1994 and its stock trades on the NASDAQ Capital Market under the ticker symbol TGEN.
|
